Head-To-Head Survey: Black Titan (BTTC) & Its Rivals

Black Titan (NASDAQ:BTTC) is one of 48 publicly-traded companies in the “Services – Computer Programming And Data Processing” industry, but how does it weigh in compared to its rivals? We will compare Black Titan to similar companies based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, risk, dividends and profitability.

Institutional & Insider Ownership

56.0% of shares of all “Services – Computer Programming And Data Processing” companies are held by institutional investors. 0.7% of Black Titan shares are held by insiders. Comparatively, 16.3% of shares of all “Services – Computer Programming And Data Processing” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Black Titan has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s rivals have a beta of 0.68, meaning that their average share price is 32% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Black Titan and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	100	199	219	12	2.27

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 130.21%. Given Black Titan’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Black Titan has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Black Titan and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.64
Black Titan Competitors	$233.22 million	-$56.16 million	-9.41

Black Titan’s rivals have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Black Titan and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-51.37%	-912.76%	-63.13%

Summary

Black Titan rivals beat Black Titan on 8 of the 12 factors compared.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.